 |
||
 |
||
 |
||
 |
||
 |
|
|
|
|
|
|
New Initiatives 2008 | |
|
|
Researchers |
|
|
|
|
|
|
|
|
|
|
||
 |
||
 |
||
 |
||
 |
||
 |
||
 |
||
 |
||
 |
||
Gary
Gilliland received his PhD in microbiology from the University of California-Los
Angeles and his MD from the University of California-San Francisco. He
completed his medical internship in Boston at Brigham and Women's Hospital
(BWH), where he was chief medical resident, and did hematology and oncology
training at BWH and the Dana-Farber Cancer Institute (DFCI). He has been
on the faculty at Harvard Medical School (HMS) since that time, and is
currently professor of medicine and a faculty member of the graduate program
in Biological and Biomedical Sciences at HMS; an investigator at the Howard
Hughes Medical Institute; director of the Leukemia Program for the DFCI/Harvard
Cancer Center; and director of the Cancer Stem Cell Program of the Harvard
Stem Cell Institute. Dr. Gilliland's research interest is in the biology
and treatment of human cancers, with a focus on hematopoietic malignancies
and myeloproliferative disorders.
Dr.
Hoffman received his medical degree from New York University. He was a
house officer at the McGill University School of Medicine and the Stanford
University School of Medicine and was a Hematology Fellow at Mt. Sinai
School of Medicine in New York. He is a Diplomate of the American Board
of Internal Medicine/Hematology. He has held faculty positions at Yale
University School of Medicine, University of Illinois at Chicago, and the Indiana University School of Medicine. He
currently holds a faculty appointment at Mt. Sinai School of Medicine in New York. His major
research interests include myeloproliferative disorders and hematopoietic
stem cell biology. He is a Past President of The American Society of Hematology
and the International Society for Experimental Hematology. He was editor
of the journal Experimental Hematology from 1999 to 2003. He is an author
of over 300 scientific publications and is an editor of the textbook ,
Hematology: Basic Principles and Practice. His research activities are
funded by the National Institutes of Health and the Department of Defense.
Dr.
Ayalew Tefferi was born in Addis Ababa, Ethiopia and migrated to the United
States in 1982 after completing his medical school education at the University
of Athens in Athens, Greece. Dr. Tefferi received his Hematology training
at the Mayo Clinic in Rochester, MN before joining the staff at the Mayo
Clinic College of Medicine, Division of Hematology in the Department of
Medicine. He is currently a full professor in Hematology and Internal
Medicine.
Dr. Tefferi spends the majority of his time in direct patient care and his clinical as well as laboratory interests focus on the classic Philadelphia chromosome-negative myeloproliferative disorders (polycythemia vera, essential thrombocythemia, myelofibrosis with myeloid metaplasia), chronic myeloid leukemia, myelodysplastic syndrome, and the atypical myeloproliferative disorders including hypereosinophilic syndrome and systemic mast cell disease. His academic and research achievements have been copious and include over 700 publications including books, book chapters, original articles, reviews, editorials, letters, and abstracts. In addition, Dr. Tefferi serves as an associate editor for the Mayo Clinic Proceedings and serves as an editorial board member for several journals including Blood.. Dr. Tefferi has given more than 300 national and international invited lectureships and serves as faculty for the annual Hematology and Oncology Board review courses at George Washington University in Washington DC, Harvard in Boston MA, and MD Anderson Cancer Center in Houston TX.
